Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved US$ 29.59 Min. order: 1 piece ★★★★★ 4.2 (67 reviews) Sold : Login>>
Development of a Long-Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP-1R Agonists for the Treatment of Obesity US$ 28.71 Min. order: 1 piece ★★★★★ 5.0 (62 reviews) Sold : Login>>
Efficacy and Safety of Cagrilintide Alone and in... : Indian Journal of Endocrinology and Metabolism US$ 29.77 Min. order: 1 piece ★★★★★ 4.7 (202 reviews) Sold : Login>>
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: Cell Reports Medicine US$ 26.86 Min. order: 1 piece ★★★★★ 4.0 (12 reviews) Sold : Login>>
CagriSema Achieves 23% Weight Loss but Misses Noninferiority vs Tirzepatide in REDEFINE 4 US$ 27.37 Min. order: 1 piece ★★★★★ 4.4 (154 reviews) Sold : Login>>